Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will engage in a fireside chat on March 29, 2023, at 10 AM ET, hosted by EF Hutton's analyst Constantine Davides. The chat will explore Nemaura's innovative glucose monitoring device, digital health solutions, commercial strategy, and early patient data from their UK pilot program.
The company is developing non-invasive wearable sensors and has submitted a PMA for its sugarBEAT® device to the FDA. Nemaura aims to capitalize on a growing global diabetes market projected to reach nearly $59 billion by 2025.
Nemaura Medical (NASDAQ: NMRD) announced the inclusion of injectable insulin in its DuoPack Commercial License Agreement with MySugarWatch DuoPack Limited. This agreement allows Nemaura's non-invasive wearable sensors to be paired with insulin and other Type 2 diabetes medications, enhancing patient care through a holistic approach. The collaboration aims to provide access to a continuous glucose monitoring-guided insulin dosage system, potentially reducing hospital admissions and improving outcomes for approximately 4 million older diabetes patients in the UK and EU. Nemaura continues to innovate in the diabetes management market, expected to exceed $59 billion by 2025.